The two-year collaboration with the Cleveland Clinic will evaluate “the target conformity of proton mini-beams compared with x-ray stereotactic body radiation therapy”.
Advances in traditional radiation therapy have revolved around the accuracy of the procedure; namely, improving the targeting of cancerous areas, while avoiding the healthy surrounding tissue.
The use of a smaller proton beams such as AVO’s LIGHT system, which uses a mini-beam, also helps in this regard.
In fact, AVOs technology is possibly more precise than traditional proton beams.
As the approach is new and cutting edge, so medical tie-ups with centres of excellence such as the Cleveland Clinic are required to help communicate the process for the best outcomes.
The US partnership should also provide third-party validation of its kit as well as providing valuable information on the cancer advance for the profession’s key opinion leaders.
AVO’s technology is based on work by ADAM, which AVO bought in 2013 from CERN – the world’s largest particle physics lab that built the Hadron collider.
The major plus point of proton therapy is that it can pinpoint tumours more precisely, which means less damage to surrounding healthy tissues.
Proton therapy facilities have traditionally been pricey and large, requiring a space the size of a football pitch to run.
But AVO thinks it has solved that problem, and LIGHT is being built to fit in the basement of a townhouse in Harley Street, central London.
Its modular design, lighter weight and better proton efficiency also help to keep costs down, which should open proton therapy up to many more patients.
Building work at the Harley Street facility is expected to finish later this year, with the first patient on track to be treated at the facility in the second half of next year.